Evidence map›Paper›PMID 41486146›Full record

ReviewJournal of biomedical science2026

PHGDH at the crossroads: metabolic plasticity, metastatic paradoxes, and therapeutic reconnaissance in cancer.

Liang Hao, Bai-Qiang Li, Shi-Yang Lu, Zhong-Cai An, Zheng-Yuan Yin, Zhen-Xian Du, Hua-Qin Wang

Abstract readReview
In one paragraph

Review in Journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liang Hao *Department of Biochemistry & Molecular Biology, China Medical University, Shenyang, 110122, China.
Bai-Qiang Li *Department of Biochemistry & Molecular Biology, China Medical University, Shenyang, 110122, China.
Shi-Yang LuDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, 110122, China.
Zhong-Cai AnDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, 110122, China.
Zheng-Yuan YinDepartment of Endocrinology & Metabolism, The 1st Affiliated Hospital, China, Medical University, Shenyang, 110001, China.
Zhen-Xian DuDepartment of Endocrinology & Metabolism, The 1st Affiliated Hospital, China, Medical University, Shenyang, 110001, China. dzx_doctor@qq.com.
Hua-Qin WangDepartment of Biochemistry & Molecular Biology, China Medical University, Shenyang, 110122, China. hqwang@cmu.edu.cn.

Funding

National Natural Science Foundation of China 82373013Natural Science Foundation of Liaoning Province 2024JH6/100800018
6 · The paper itself

Abstract

Phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine biosynthesis pathway (SSP), is a central metabolic hub and multifunctional oncoprotein that drives tumorigenesis through both canonical and non-canonical mechanisms. This review outlines the multi-level regulation of PHGDH, covering epigenetic remodeling (DNA hypomethylation, H3K4me3/H3K36me3 dynamics), transcriptional control (ATF4, MYC, EWS-FLI1), post-transcriptional fine-tuning (m

Indexed as

NeoplasmsPhosphoglycerate DehydrogenaseAnimalsEpigenesis, GeneticHumansNeoplasm MetastasisPhosphoglycerate DehydrogenaseMetastatic heterogeneityNeurotoxicity paradoxPHGDHPrecision metabolic oncologySerine biosynthesis pathwaySpatial multi-omics

Identifiers

PMID41486146
PMCPMC12766945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.